Methods of using activin receptor type ii signaling inhibitors

Co-administration of ActRII signaling inhibitors with myelofibrosis therapies addresses myelofibrosis-related cytopenias and spleen enlargement, enhancing patient outcomes by increasing blood cell counts and reducing transfusion needs.

WO2025184284A1 Publication Date: 2025-09-04KEROS THERAPEUTICS INC
3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/017504
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-27
Filing Date
2025-02-27
Publication Date
2025-09-04

AI Technical Summary

Technical Problem

There is a need for a new therapeutic approach to ameliorate myelofibrosis-associated cytopenias, improve spleen volume, and enhance patient-reported outcomes in patients with myelofibrosis or polycythemia vera.

Method used

Co-administration of an activin receptor type II (ActRII) signaling inhibitor, such as antibodies or ligand traps, in combination with myelofibrosis therapies like momelotinib or hydroxyurea, to treat myelofibrosis, cytopenias, and polycythemia vera, reducing spleen volume and improving patient-reported outcomes.

Benefits of technology

The combination therapy effectively reduces cytopenias, decreases spleen volume, and enhances patient-reported outcomes by increasing red blood cell and platelet counts, reducing transfusion burden, and improving quality of life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention features methods of treating a subject having myelofibrosis by co-administering an activin receptor type II (ActRII) signaling inhibitor and a myelofibrosis therapy. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, an ActRII ligand trap, or an anti-myostatin adnectin recombinant protein.
Need to check novelty before this filing date? Find Prior Art